TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01463748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graptopetalum paraguayense E. Walther
Description: Graptopetalum paraguayense E. Walther
Study: NCT01598493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flamazine
Description: Silver sulfadiazine cream
Study: NCT01463748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: starch
Study: NCT03053050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablets administered orally once daily
Study: NCT04010981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study group
Description: The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
Study: NCT03053050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily
Study: NCT02779153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar low dose (40 U)
Description: The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar high dose (80 U)
Description: The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
Study: NCT05985187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2440 injection + Trastuzumab + Docetaxel
Description: TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta + Trastuzumab + Docetaxel
Description: Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance.
Study: NCT03593655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Description: Vaginal ring containing 25 mg of dapivirine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Description: Vaginal ring containing 25 mg of dapivirine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Tablet containing 200 mg FTC/300 mg TDF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Tablet containing 200 mg FTC/300 mg TDF
Study: NCT03899883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 MG/ML [Krystexxa]
Description: One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
Study: NCT02741726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: Electric stimulation was given through electrode attached to acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: Electric stimulation was given through electrode attached to acupoints

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: no stimulation
Description: patients were only attached electrodes without electric current
Study: NCT00550043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424
Study: NCT02703675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excel Cryo Cooling Collar
Description: Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excel Cryo Cooling Collar
Description: Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excel Cryo Cooling Collar
Description: Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
Study: NCT03462030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baked non-fat cow's milk powder
Description: Oral immunotherapy with increasing quantities of baked milk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Tapioca Powder
Description: Placebo control.
Study: NCT03435133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 60 mg oral bolus plus oral 10 mg once daily
Study: NCT04010981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
Study: NCT02125656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
Study: NCT03435133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 180 mg oral bolus plus oral 90 mg every 12 hours daily
Study: NCT03518177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation
Description: The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
Study: NCT00550043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03278327

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.
Description: Endoscopic resection treatment

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic resection at month 2 and month 4
Description: System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane.
Study: NCT01749475

Intervention type: DRUG
Intervention: Midazolam
Description: The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
Study: NCT03850678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid
Description: Hearing Aid
Study: NCT06182631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy Bee
Description: The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapocoolent
Description: Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
Study: NCT03845517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01749475

Intervention type: OTHER
Intervention: hypnotherapy
Description: A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
Study: NCT02450149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Study: NCT01610817

Intervention type: OTHER
Intervention: InPAct : Information for Participating Actively in cardiovascular treatment
Description: Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
Study: NCT03872206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN536 Fixed IV 6 to 560 ng/kg
Description: Fixed dose IV cohorts at doses from 6 to 560 ng/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN536 1 Prime Step IV 600-1200 ng/kg Target
Description: Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 Prime Step IV 900-14000 ng/kg Target
Description: Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
Study: NCT01285362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil Supplementation
Description: Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
Study: NCT04150978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Polymeric Formula
Description: Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oligomeric Formula
Description: Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Dextrose
Description: 500 ml of 5% Dextrose administered to a peripheral vein.
Study: NCT00687544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (SCH 054031)
Description: Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 018908)
Description: Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
Study: NCT03078764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health system
Description: Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail reports and technical support for mHealth system
Description: Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
Study: NCT01414582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: All participants will receive a standardised motor training intervention for the upper paretic limb

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Training
Description: All participants will receive a standardised motor training intervention for the upper paretic limb
Study: NCT01761604

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal ganglion block for TN
Study: NCT02861105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline solution
Description: 0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
Study: NCT04171336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Description: Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
Study: NCT04166942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD025
Description: Single dose of 200 mg KD025 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD025
Description: Single dose of 200 mg KD025 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD025
Description: Single dose of 200 mg KD025 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD025
Description: Single dose of 200 mg KD025 orally
Study: NCT02448394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Support Worker
Description: At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
Study: NCT03732937

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Ultrasonography with biometry and TCD measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Ultrasonography with biometry and TCD measurement
Study: NCT02095691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celsius® ThermoCool® Renal Denervation
Description: The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
Study: NCT02522364

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioMonitor device
Description: Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Clinical and intermittent electrocardiographic follow-up of patients
Study: NCT02792712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg LD，then 90 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 300 mg LD，then 75 mg QD
Study: NCT00418860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, Clopidogrel
Description: Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
Study: NCT03478644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Denture Wipe
Description: Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap Water
Description: Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
Study: NCT04137081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based mindfulness training
Description: Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
Study: NCT02137213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be added to oral methadone preparations as placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be added to oral methadone preparations as placebo.
Study: NCT05014659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: 4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
Study: NCT00789698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HC1
Description: Lurasidone 40-160 mg/day flexibly dosed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Quetiapine XR 200-800 mg/day flexibly dosed.
Study: NCT04438837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine post exposure prohylaxis